Home » Authors » Brady Huggett

Articles by Brady Huggett

Invitrogen Prices $325M Worth Of Notes, Keeps Buying Power

July 30, 2003

By Brady Huggett

Invitrogen Prices $325M Worth Of Notes, Keeps Buying Power

July 30, 2003

By Brady Huggett

OxiGene Gets Orphan Status For CA4P; Stock Soars 50 Percent

July 29, 2003

By Brady Huggett

OxiGene Gets Orphan Status For CA4P; Stock Soars 50 Percent

July 29, 2003

By Brady Huggett

Antegren's Miss In Crohn's Mars Respectable Earnings For Biogen

July 25, 2003

By Brady Huggett

Biogen Inc. and partner Elan Corp. plc released disappointing Phase III data on Antegren in an induction trial in Crohn's disease, dragging both companies' stocks down and overshadowing positive second-quarter figures for Biogen. (BioWorld Today)

Antegren's Miss In Crohn's Mars Respectable Earnings For Biogen

July 25, 2003

By Brady Huggett

Biogen Inc. and partner Elan Corp. plc released disappointing Phase III data on Antegren in an induction trial in Crohn's disease, dragging both companies' stocks down and overshadowing positive second-quarter figures for Biogen. (BioWorld Today)

Diversa Acquiring GSK Antifungal Compounds For $8.6M In Equity

July 23, 2003

By Brady Huggett

Diversa Acquiring GSK Antifungal Compounds For $8.6M In Equity

July 23, 2003

By Brady Huggett

Medarex Raises $100M Via Notes Sale, Adds To Financing Flurry

July 21, 2003

By Brady Huggett

Medarex Raises $100M Via Notes Sale, Adds To Financing Flurry

July 21, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Feb. 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...